Holen Sie sich die Stockscreener-App
137.23
0.09%
-0.12
Handel nachbörslich:
137.23
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Can Neurocrine Biosciences Inc. stock maintain growth trajectoryWeekly Trade Recap & Real-Time Stock Movement Alerts - newser.com
What moving averages say about Neurocrine Biosciences Inc.Day Trade & Free Risk Controlled Daily Trade Plans - newser.com
Does the Recent Rare Earths News Move the Needle for Neurocrine Biosciences Valuation? - simplywall.st
Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
United States Huntington's Disease Market is expected to reach - openPR.com
Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionMarket Risk Analysis & Growth Focused Stock Reports - newser.com
Is Neurocrine Biosciences Inc a good long term investmentChart Pattern Recognition & Ride the Trends That Billionaires Follow - earlytimes.in
Neurocrine Biosciences (NBIX): Evaluating Valuation Following Recent Clinical Milestones and Leadership Appointment - simplywall.st
Using data models to predict Neurocrine Biosciences Inc. stock movementOil Prices & Weekly Top Gainers Trade List - newser.com
Market reaction to Neurocrine Biosciences Inc.’s recent newsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
UBS Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Using economic indicators to assess Neurocrine Biosciences Inc. potential2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
Neurocrine Biosciences' (NBIX) "Hold (C+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How to forecast Neurocrine Biosciences Inc. trends using time seriesJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com
Full technical analysis of Neurocrine Biosciences Inc. stockJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Neurocrine Bio. stock price target raised to $195 from $188 at UBS - Investing.com Nigeria
UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating - MarketScreener
Why Neurocrine Biosciences Inc. (NB3) stock fits value portfoliosQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Neurocrine Biosciences publishes positive data from movement disorder study - MSN
RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating - MarketScreener
Truist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - Eastern Progress
Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc. - MarketBeat
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise - Investing.com
20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com
Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com
Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com
Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider
Neurocrine Demonstrates 77.8% PGI-C Response at 3 Years | NBIX Stock News - Stock Titan
Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com
What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st
Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com
What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com
Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail
Pure Financial Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st
1.30%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):